Title:
TREATMENT OF PROSTATE CANCER USING CHIMERIC ANTIGEN RECEPTORS
Document Type and Number:
WIPO Patent Application WO/2019/204827
Kind Code:
A3
Abstract:
Provided herein are methods of treating neuroendocrine prostate cancer (NEPC) with immune cells comprising a CEACAM5 chimeric antigen receptor (CAR). Also provided are methods of reducing or eliminating NEPC cancer cells with immune cells comprising a CEACAM5 CAR. Also provided are methods of treating a cancer with a molecular signature that is similar to a molecular signature of NEPC (e.g., small cell lung cancer (SCLC), small cell carcinoma of the pancreas (SCCP), or small cell prostate cancer).
Inventors:
WITTE OWEN (US)
LEE JOHN (US)
BANGAYAN NATHANAEL (US)
LEE JOHN (US)
BANGAYAN NATHANAEL (US)
Application Number:
PCT/US2019/028577
Publication Date:
December 19, 2019
Filing Date:
April 22, 2019
Export Citation:
Assignee:
UNIV CALIFORNIA (US)
International Classes:
C07K16/18; A61K35/17; A61K39/395; C07K16/30; C12N5/0783
Foreign References:
| US20160122766A1 | 2016-05-05 | |||
| US20180104308A1 | 2018-04-19 | |||
| US20150125386A1 | 2015-05-07 |
Other References:
MADHUSOODANAN ET AL., WITH NEW CAR T APPROACH, CITY OF HOPE CEACAM COMES FULL CIRCLE, 9 February 2018 (2018-02-09), XP009524319, Retrieved from the Internet [retrieved on 20190829]
Attorney, Agent or Firm:
STELLMAN, Laurie, F. (US)
Download PDF: